These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Soluble urokinase plasminogen activator receptor level is an independent predictor of the presence and severity of coronary artery disease and of future adverse events. Eapen DJ; Manocha P; Ghasemzadeh N; Patel RS; Al Kassem H; Hammadah M; Veledar E; Le NA; Pielak T; Thorball CW; Velegraki A; Kremastinos DT; Lerakis S; Sperling L; Quyyumi AA J Am Heart Assoc; 2014 Oct; 3(5):e001118. PubMed ID: 25341887 [TBL] [Abstract][Full Text] [Related]
8. Sex Differences in Circulating Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels and Adverse Outcomes in Coronary Artery Disease. Mehta A; Desai SR; Ko YA; Liu C; Dhindsa DS; Nayak A; Hooda A; Martini MA; Ejaz K; Sperling LS; Reiser J; Hayek SS; Quyyumi AA J Am Heart Assoc; 2020 Mar; 9(5):e015457. PubMed ID: 32089048 [TBL] [Abstract][Full Text] [Related]
9. Single-Molecule Counting of High-Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular Diseases) Study. McCarthy CP; Ibrahim NE; Lyass A; Li Y; Gaggin HK; Simon ML; Mukai R; Gandhi P; Kelly N; Motiwala SR; van Kimmenade RRJ; Massaro JM; D'Agostino RB; Januzzi JL J Am Heart Assoc; 2018 Mar; 7(6):. PubMed ID: 29519811 [TBL] [Abstract][Full Text] [Related]
10. Soluble urokinase plasminogen activator receptor as a long-term prognostic biomarker in acute coronary syndromes. Peiró ÓM; Cediel G; Bonet G; Rojas S; Quintern V; Carrasquer A; González-Del-Hoyo M; Sanz E; Bardají A Biomarkers; 2020 Jul; 25(5):402-409. PubMed ID: 32551985 [No Abstract] [Full Text] [Related]